Evidence map›Paper›PMID 27401257›Full record

ArticleCancer medicine2016

Maitake Pro4X has anti-cancer activity and prevents oncogenesis in BALBc mice.

Agustina Roldan-Deamicis, Eliana Alonso, Belén Brie, Diego Aguilera Braico, Gabriela Andrea Balogh

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Agustina Roldan-DeamicisInstituto de Investigaciones Biomédicas, Facultad de Ciencias Medicas, Pontificia Universidad Católica Argentina - UCA - CONICET, Buenos Aires, Argentina.
Eliana AlonsoLaboratorio de Hongos Comestibles y Medicinales, Centro Científico Tecnológico, CERZOS-CONICET, Camino La Carrindanga Km7, Bahía Blanca-8000, Buenos Aires, Argentina.
Belén BrieInstituto de Investigaciones Biomédicas, Facultad de Ciencias Medicas, Pontificia Universidad Católica Argentina - UCA - CONICET, Buenos Aires, Argentina.
Diego Aguilera BraicoInstituto de Investigaciones Biomédicas, Facultad de Ciencias Medicas, Pontificia Universidad Católica Argentina - UCA - CONICET, Buenos Aires, Argentina.
Gabriela Andrea BaloghInstituto de Investigaciones Biomédicas, Facultad de Ciencias Medicas, Pontificia Universidad Católica Argentina - UCA - CONICET, Buenos Aires, Argentina. gabriela_balogh@uca.edu.ar.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARCentro Científico Tecnológico - Bahía Blanca · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The understanding of the molecular mechanisms of the immune tolerance induced by the tumoral microenvironment is fundamental to prevent cancer development or to treat cancer patients using immunotherapy. Actually, there are investigations about "addressed-drugs" against cancer cells without affecting normal cells. It could be ideal to find selective and specific compounds that only recognize and destroy tumor cells without damaging the host normal cells. For thousands of years, mushrooms have been used for medicinal purposes because of their curative properties. D-Fraction, an extract of Maitake (from the edible Grifola frondosa mushroom), rich in β-glucans, exert notable effects in the immune system. Until now, some published articles suggest that Maitake D-Fraction could have anti-tumoral activity, prevent oncogenesis and metastasis in some tumor types. However, there are no clear data about Maitake D-Fraction action on breast cancer prevention and its exact molecular mechanisms are not yet elucidated. The experiments were performed employing 25 female BALBc mice that were treated with and without Maitake D-Fraction Pro4X or Maitake Standard for 15 days by daily intraperitoneal injection. After treatment period, all mice were implanted with murine tumor cells LM3 to induce mammary tumorigenesis. Animals were checked weekly and killed after 46 days of LM3 transplant; percentage of cancer prevention, rate of tumor growing, and overall survival were determined. Under dissection, the internal organs were evaluated histologically and genetically by RT-PCR. We found that 5 mg/kg per day of Maitake D-Fraction Pro4X, administered dairy during 15 days to BALBc mice was able to block more than 60% breast cancer development. However, Maitake Standard prevents oncogenesis in 26% to respect control. In this work, we found that Maitake D-Fraction Pro4X, administered to BALBc mice, prevents breast carcinogenesis, block tumor invasiveness, reduce angiogenesis, and increase overall survival.

Indexed as

AnimalsAntineoplastic AgentsBiological ProductsBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticGrifolaMiceMortalityNecrosisNeovascularization, PathologicPhenotypeXenograft Model Antitumor AssaysAntineoplastic AgentsBiological ProductsBreast cancercancer preventioncarcinogenesisMaitake Pro4X

Identifiers

PMID27401257
PMCPMC5055164
OpenAlexW2474043456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.